Key result
Biallelic deletion of FHL2 reduced the number of intestinal polyps by 68% in ApcD14/+ mutant mice compared to wild-type littermates.
Why the study?
Does FHL2 deficiency reduce intestinal tumorigenesis in Apc mutant mice?
Does FHL2 deficiency reduce intestinal tumorigenesis in Apc mutant mice?
Effect estimate: 68% reduction
p-value: p=<0.0001
FHL2 deficiency significantly reduces the number of intestinal adenomas in Apc mutant mice, highlighting its critical role in the initial steps of intestinal tumorigenesis.
FHL2 loss curbs Apc-driven intestinal tumors in mice; leaves open its role and targeting potential in human colorectal cancer.
BACKGROUND: The four and a half LIM-only protein 2 (FHL2) is capable of shuttling between focal adhesion and nucleus where it signals through direct interaction with a number of proteins including beta-catenin. Although FHL2 activation has been found in various human cancers, evidence of its functional contribution to carcinogenesis has been lacking. METHODOLOGY/PRINCIPAL FINDINGS: Here we have investigated the role of FHL2 in intestinal tumorigenesis in which activation of the Wnt pathway by mutations in the adenomatous polyposis coli gene (Apc) or in beta-catenin constitutes the primary transforming event. In this murine model, introduction of a biallelic deletion of FHL2 into mutant Apc(Delta14/+) mice substantially reduces the number of intestinal adenomas but not tumor growth, suggesting a role of FHL2 in the initial steps of tumorigenesis. In the lesions, Wnt signalling is not affected by FHL2 deficiency, remaining constitutively active. Nevertheless, loss of FHL2 activity is associated with increased epithelial cell migration in intestinal epithelium, which might allow to eliminate more efficiently deleterious cells and reduce the risk of tumorigenesis. This finding may provide a mechanistic basis for tumor suppression by FHL2 deficiency. In human colorectal carcinoma but not in low-grade dysplasia, we detected up-regulation and enhanced nuclear localization of FHL2, indicating the activation of FHL2 during the development of malignancy. CONCLUSIONS/SIGNIFICANCE: Our data demonstrate that FHL2 represents a critical factor in intestinal tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Labalette et al. (2010) studied Intestinal tumorigenesis (n=45). FHL2 deficiency vs. FHL2 wild-type (FHL2+/+) was evaluated on Total number of intestinal polyps (68% reduction, p=<0.0001). Biallelic deletion of FHL2 reduced the number of intestinal polyps by 68% in ApcD14/+ mutant mice compared to wild-type littermates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: